Serum Thymidine Kinase Levels in Acute Leukaemia
Author Information
Author(s): H. Hagberg, S. Gronowitz, A. Killander, C. Killander, B. Simonsson, C. Sundström, G. Obergi
Primary Institution: University Hospital, Uppsala, Sweden
Hypothesis
How does the pretreatment level of serum thymidine kinase correlate with the type of acute leukaemia, the remission rate, and the duration of remission?
Conclusion
The pretreatment level of serum thymidine kinase is elevated in almost all patients with acute leukaemia and correlates with the remission rate.
Supporting Evidence
- Elevated serum thymidine kinase levels were observed in patients with various malignant diseases.
- Significant correlations were found between serum thymidine kinase levels and both peripheral blast cell count and degree of leukaemic bone marrow infiltration.
- Patients with therapy-resistant leukaemia had higher pretreatment serum thymidine kinase values.
Takeaway
Doctors measured a substance in the blood called thymidine kinase to see if it could help predict how well patients with leukemia would respond to treatment.
Methodology
The study analyzed serum thymidine kinase levels in patients diagnosed with acute leukaemia and correlated these levels with treatment outcomes.
Limitations
The study's sample size is too small to draw definitive conclusions about the clinical usefulness of the S-TK assay.
Participant Demographics
The study included 66 patients with acute leukaemia, 54 with AML and 12 with ALL, with a mean age of 46 for AML and 36 for ALL.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website